Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00389207
First received: October 17, 2006
Last updated: December 9, 2013
Last verified: December 2013
Results First Received: January 13, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: nevirapine bid
Drug: nevirapine qd
Drug: atazanavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Nevirapine QD Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir Atazanvir 300mg QD boosted by ritonavir 100mg QD (ATZ/r) on a background of the fixed combination Truvada®

Participant Flow:   Overall Study
    Nevirapine QD     Nevirapine BID     Atazanvir/Ritonavir  
STARTED     188 [1]   188 [2]   193  
COMPLETED     125     116     152  
NOT COMPLETED     63     72     41  
Adverse Event                 26                 32                 10  
Protocol Violation                 3                 1                 4  
Lost to Follow-up                 12                 9                 7  
Withdrawal by Subject                 5                 7                 11  
Not specified                 17                 23                 9  
[1] 3 patients were randomized to NVP QD but not treated and so not part of the Full Analysis Set (FAS)
[2] 4 patients were randomized to NVP BID but not treated and so are not part of the FAS



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Nevirapine QD Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir ATZ/r on a background of the fixed combination Truvada®
Total Total of all reporting groups

Baseline Measures
    Nevirapine QD     Nevirapine BID     Atazanvir/Ritonavir     Total  
Number of Participants  
[units: participants]
  188     188     193     569  
Age  
[units: years]
Mean ± Standard Deviation
  38.4  ± 9.7     40.0  ± 10.5     37.6  ± 9.5     38.6  ± 9.9  
Gender  
[units: participants]
       
Female     36     25     31     92  
Male     152     163     162     477  
Baseline HIV viral load category  
[units: participants]
       
Baseline HIV viral load ≤ 100,000 copies/mL     71     71     65     207  
Baseline HIV viral load > 100,000 copies/mL     117     117     128     362  
Baseline log10 HIV viral load [1]
[units: log¬†10¬†Copies/mL]
Mean ± Standard Deviation
  5.1  ± 0.7     5.1  ± 0.6     5.1  ± 0.7     5.1  ± 0.7  
Baseline CD4+ cell count [1]
[units: Cells/mm^3]
Mean ± Standard Deviation
  183.3  ± 95.5     202.9  ± 93.6     193.2  ± 95.8     193.2  ± 95.1  
[1] 185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Treatment Response at Week 48   [ Time Frame: From baseline to Week 48 ]

2.  Secondary:   Treatment Response at Week 48 (TLOVR Algorithm)   [ Time Frame: From baseline to Week 48 ]

3.  Secondary:   Proportion of Patients With VL < 50 Copies/ml   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

4.  Secondary:   Proportion of Patients With VL < 400 Copies/ml   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

5.  Secondary:   Change in CD4+ Count From Baseline   [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

6.  Secondary:   Change in Framingham Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

7.  Secondary:   Change in Mental Health Summary (MHS) Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

8.  Secondary:   Change in Physical Health Summary (PHS) Score From Baseline   [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

9.  Secondary:   Number of Patients Hospitalized   [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

10.  Secondary:   Non-scheduled Physician Visits   [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

11.  Secondary:   Genotypic Resistance Associated With Virologic Failure   [ Time Frame: From baseline to Week 48 ]

12.  Secondary:   Treatment-emergent AIDS-defining Illness   [ Time Frame: From baseline to Week 144 ]

13.  Secondary:   Treatment-emergent AIDS-defining Illness Leading to Death   [ Time Frame: From baseline to Week 144 ]

14.  Secondary:   Lipodystrophy   [ Time Frame: From baseline to Week 144 ]

15.  Secondary:   Serum Lipid Abnormalities   [ Time Frame: From baseline to Week 144 ]

16.  Secondary:   Glycaemic Abnormalities   [ Time Frame: From baseline to Week 144 ]

17.  Secondary:   Treatment Response at Week 96   [ Time Frame: From baseline to Week 96 ]

18.  Secondary:   Treatment Response at Week 144   [ Time Frame: From baseline to Week 144 ]

19.  Secondary:   Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144   [ Time Frame: at Week 24, 48, 96, 144 ]

20.  Secondary:   Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144   [ Time Frame: at Week 24, 48, 96, 144 ]

21.  Secondary:   Proportion of Patients With Virologic Failure at Week 48, 96, 144   [ Time Frame: at Week 48, 96, 144 ]

22.  Secondary:   Time to Treatment Response (First Confirmed VL<50 Copies/mL)   [ Time Frame: baseline to week 144 ]

23.  Secondary:   Time to Loss of Virologic Response (Rebound)   [ Time Frame: Baseline to week 144 ]

24.  Secondary:   Time to Treatment Failure   [ Time Frame: baseline to week 144 ]

25.  Secondary:   Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144   [ Time Frame: From baseline to Week 48, 96, 144 ]

26.  Secondary:   Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities   [ Time Frame: week 148 ]

27.  Secondary:   Proportion of Patients Reporting Rash of Any Severity   [ Time Frame: week 148 ]

28.  Secondary:   Proportion of Patients Reporting Hepatic Events of Any Severity   [ Time Frame: week 148 ]

29.  Secondary:   Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity   [ Time Frame: week 148 ]

30.  Secondary:   Change of Cholesterol Values From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

31.  Secondary:   Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

32.  Secondary:   Change of hsCRP From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

33.  Secondary:   Change of Total Triglycerides From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]

34.  Secondary:   Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144   [ Time Frame: baseline to week 48, 96, 144 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame 148 weeks
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Nevirapine QD NVP 400mg QD on a background of the fixed combination Truvada®
Nevirapine BID NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir ATZ/r on a background of the fixed combination Truvada®

Other Adverse Events
    Nevirapine QD     Nevirapine BID     Atazanvir/Ritonavir  
Total, other (not including serious) adverse events        
# participants affected / at risk     136/188     141/188     161/193  
Eye disorders        
Ocular icterus † 1      
# participants affected / at risk     0/188 (0.00%)     0/188 (0.00%)     14/193 (7.25%)  
Gastrointestinal disorders        
Abdominal pain † 1      
# participants affected / at risk     5/188 (2.66%)     10/188 (5.32%)     15/193 (7.77%)  
Abdominal pain upper † 1      
# participants affected / at risk     9/188 (4.79%)     14/188 (7.45%)     13/193 (6.74%)  
Diarrhoea † 1      
# participants affected / at risk     29/188 (15.43%)     33/188 (17.55%)     47/193 (24.35%)  
Flatulence † 1      
# participants affected / at risk     9/188 (4.79%)     10/188 (5.32%)     9/193 (4.66%)  
Nausea † 1      
# participants affected / at risk     22/188 (11.70%)     21/188 (11.17%)     21/193 (10.88%)  
Vomiting † 1      
# participants affected / at risk     13/188 (6.91%)     15/188 (7.98%)     8/193 (4.15%)  
General disorders        
Fatigue † 1      
# participants affected / at risk     11/188 (5.85%)     11/188 (5.85%)     12/193 (6.22%)  
Influenza like illness † 1      
# participants affected / at risk     10/188 (5.32%)     6/188 (3.19%)     9/193 (4.66%)  
Pyrexia † 1      
# participants affected / at risk     14/188 (7.45%)     13/188 (6.91%)     9/193 (4.66%)  
Hepatobiliary disorders        
Hyperbilirubinaemia † 1      
# participants affected / at risk     0/188 (0.00%)     0/188 (0.00%)     15/193 (7.77%)  
Jaundice † 1      
# participants affected / at risk     0/188 (0.00%)     0/188 (0.00%)     40/193 (20.73%)  
Infections and infestations        
Bronchitis † 1      
# participants affected / at risk     28/188 (14.89%)     19/188 (10.11%)     19/193 (9.84%)  
Gastroenteritis † 1      
# participants affected / at risk     8/188 (4.26%)     14/188 (7.45%)     8/193 (4.15%)  
Gonorrhoea † 1      
# participants affected / at risk     11/188 (5.85%)     3/188 (1.60%)     4/193 (2.07%)  
Herpes zoster † 1      
# participants affected / at risk     16/188 (8.51%)     12/188 (6.38%)     7/193 (3.63%)  
Influenza † 1      
# participants affected / at risk     21/188 (11.17%)     18/188 (9.57%)     16/193 (8.29%)  
Nasopharyngitis † 1      
# participants affected / at risk     41/188 (21.81%)     36/188 (19.15%)     40/193 (20.73%)  
Pharyngitis † 1      
# participants affected / at risk     10/188 (5.32%)     10/188 (5.32%)     12/193 (6.22%)  
Rhinitis † 1      
# participants affected / at risk     8/188 (4.26%)     7/188 (3.72%)     13/193 (6.74%)  
Sinusitis † 1      
# participants affected / at risk     13/188 (6.91%)     9/188 (4.79%)     10/193 (5.18%)  
Upper respiratory tract infection † 1      
# participants affected / at risk     6/188 (3.19%)     8/188 (4.26%)     14/193 (7.25%)  
Investigations        
Blood bilirubin increased † 1      
# participants affected / at risk     0/188 (0.00%)     1/188 (0.53%)     33/193 (17.10%)  
Musculoskeletal and connective tissue disorders        
Arthralgia † 1      
# participants affected / at risk     14/188 (7.45%)     8/188 (4.26%)     11/193 (5.70%)  
Back pain † 1      
# participants affected / at risk     14/188 (7.45%)     13/188 (6.91%)     17/193 (8.81%)  
Myalgia † 1      
# participants affected / at risk     12/188 (6.38%)     10/188 (5.32%)     9/193 (4.66%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)        
Skin papilloma † 1      
# participants affected / at risk     1/188 (0.53%)     0/188 (0.00%)     11/193 (5.70%)  
Nervous system disorders        
Headache † 1      
# participants affected / at risk     27/188 (14.36%)     24/188 (12.77%)     35/193 (18.13%)  
Psychiatric disorders        
Depression † 1      
# participants affected / at risk     16/188 (8.51%)     9/188 (4.79%)     18/193 (9.33%)  
Respiratory, thoracic and mediastinal disorders        
Cough † 1      
# participants affected / at risk     18/188 (9.57%)     22/188 (11.70%)     21/193 (10.88%)  
Oropharyngeal pain † 1      
# participants affected / at risk     6/188 (3.19%)     4/188 (2.13%)     12/193 (6.22%)  
Skin and subcutaneous tissue disorders        
Rash † 1      
# participants affected / at risk     25/188 (13.30%)     31/188 (16.49%)     23/193 (11.92%)  
Vascular disorders        
Hypertension † 1      
# participants affected / at risk     10/188 (5.32%)     9/188 (4.79%)     9/193 (4.66%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information